Ascendis Pharma Enters Achondroplasia Market with FDA Accelerated Approval of Weekly Drug YUVIWEL on March 02, 2026 Achondroplasia Approved Ascendis Pharma CNP gene navepegritide TransCon United States Food and Drug Administration YUVIWEL +
FDA Delays Decision on Ascendis' Dwarfism Drug by Three Months on November 26, 2025 Achondroplasia Approved Ascendis Pharma CNP gene Deferred Dwarfism navepegritide PDUFA post-marketing requirement TransCon United States Food and Drug Administration +